drugset / Trial / NCT07426822
Rash & Diarrhea Prophylaxis With Capivasertib
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a randomized, multicenter, phase II clinical trial evaluating prophylactic strategies to mitigate common toxicities associated with capivasertib in combination with fulvestrant in participants with hormone receptor-positive (HR+), HER2-negative advanced breast cancer who are eligible for this treatment regimen.
Timeline
- Start
- 2026-04
- Primary completion
- 2027-04
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Loperamide | Small molecule | 2 mg | Oral |
| Background | Capivasertib | Small molecule | 400 mg | Oral |
| Background | Ceterizine | Unknown | 10 mg | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |